Increased serum brain-derived neurotrophic factor levels following electroconvulsive therapy or antipsychotic treatment in patients with schizophrenia

Li, J.; Ye, F.; Xiao, Wenhuan; Tang, Xiaochen; Sha, Wei; Zhang, X.; Wang, J.

doi:10.1016/j.eurpsy.2016.03.005

Cited by 38 publications

(58 citation statements)

References 49 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Many theories of the mechanisms of action of ECT have been proposed, including the enhancement of dopamine synthesis and turnover, 42 direct effects of convulsions, 43 and increases in the secretion of BDNF 8, 9 and neurogenesis. 44 These hypotheses have gained traction from experimental studies.…”

Section: Discussionmentioning

confidence: 99%

“…Recent studies have demonstrated that ECT in schizophrenia patients alters cerebral blood flow in the prefrontal cortex (PFC), 6 increases structural network strength in the medial temporal lobe (MTL) network and lateral prefrontal/cingulate cortical network, 7 increases brain-derived neurotrophic factor (BDNF) levels, 8, 9 and improves psychotic symptoms. These results suggest that ECT can alter brain connectivity patterns, thereby alleviating symptoms of schizophrenia.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Electroconvulsive therapy-induced brain functional connectivity predicts therapeutic efficacy in patients with schizophrenia: a multivariate pattern recognition study

et al. 2017

View full text Add to dashboard Cite

Previous studies suggested that electroconvulsive therapy can influence regional metabolism and dopamine signaling, thereby alleviating symptoms of schizophrenia. It remains unclear what patients may benefit more from the treatment. The present study sought to identify biomarkers that predict the electroconvulsive therapy response in individual patients. Thirty-four schizophrenia patients and 34 controls were included in this study. Patients were scanned prior to treatment and after 6 weeks of treatment with antipsychotics only (n = 16) or a combination of antipsychotics and electroconvulsive therapy (n = 13). Subject-specific intrinsic connectivity networks were computed for each subject using a group information-guided independent component analysis technique. Classifiers were built to distinguish patients from controls and quantify brain states based on intrinsic connectivity networks. A general linear model was built on the classification scores of first scan (referred to as baseline classification scores) to predict treatment response. Classifiers built on the default mode network, the temporal lobe network, the language network, the corticostriatal network, the frontal-parietal network, and the cerebellum achieved a cross-validated classification accuracy of 83.82%, with specificity of 91.18% and sensitivity of 76.47%. After the electroconvulsive therapy, psychosis symptoms of the patients were relieved and classification scores of the patients were decreased. Moreover, the baseline classification scores were predictive for the treatment outcome. Schizophrenia patients exhibited functional deviations in multiple intrinsic connectivity networks which were able to distinguish patients from healthy controls at an individual level. Patients with lower classification scores prior to treatment had better treatment outcome, indicating that the baseline classification scores before treatment is a good predictor for treatment outcome.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Electroconvulsive therapy-induced brain functional connectivity predicts therapeutic efficacy in patients with schizophrenia: a multivariate pattern recognition study

et al. 2017

View full text Add to dashboard Cite

show abstract

“…In previous studies, the positive effects of ECT every other day have been reported for the PANSS and BPRS indices for TRS [17-20]. Furthermore, other studies have confirmed the positive effects of a combination of ECT and drugs such as clozapine and antipsychotics on schizophrenic patients’ psychiatric symptoms as measured with the BPRS and PANSS [14, 39-41]. …”

Section: Discussionmentioning

confidence: 63%

“…In a meta-analysis, Gu et al [40] described findings consistent with the present study and concluded that, for patients with schizophrenia, treatment with ECT (without concurrent use of antipsychotics), or the combination of ECT and antipsychotics, was associated with a decrease in the PANSS score. Li et al [41] found that the PANSS score in patients with schizophrenia decreased from baseline to discharge during the use of ECT. Jiang et al [17] observed that PANSS scores dropped after 7 or 8 sessions of the use of ECT (given every second day) in women with schizophrenia.…”

Section: Discussionmentioning

confidence: 99%

A Pilot Study on Daily Intensive ECT over 8 Days Improved Positive and Negative Symptoms and General Psychopathology of Patients with Treatment-Resistant Schizophrenia up to 4 Weeks after Treatment

et al. 2018

View full text Add to dashboard Cite

Objective: For patients with treatment-resistant schizophrenia (TRS) who do not respond to drug therapy, electroconvulsive therapy (ECT) is often employed as an additional treatment. The aims of the present study were to investigate to what extent an 8-day daily ECT treatment might reduce symptoms of schizophrenia among patients with TRS both in the short term (end of the treatment) and medium term, that is 4 and 12 weeks after the treatment. Methods: Fourteen patients with TRS based on DSM-5 criteria took part in the present study. ECT consisted of daily sessions for 8 consecutive days. At baseline, at the end of the intervention, and 4 and 12 weeks after study completion, trained psychiatrists assessed the patients’ disease severity (positive and negative symptoms; psychopathology) and cognitive functions. Results: Disease symptoms (positive and negative symptoms; psychopathology) became reduced from baseline to the end of the intervention and to 4 weeks after treatment. Twelve weeks after the intervention symptoms again increased. Cognitive functions decreased from baseline to the end of the study and 4 weeks after treatment. However, by 12 weeks after the intervention, cognitive functions had returned to baseline levels. Conclusion: The pattern of results suggests that an intensive 8-day daily course of ECT reduced psychiatric symptoms (positive and negative symptoms, psychopathology) in both the short and medium term among patients with TRS. The increase in symptoms between 4 and 12 weeks following intervention suggests that booster sessions of ECT could be beneficial.

show abstract

“…In a previous study, we measured serum brain derived neurotrophic factor (BDNF) in 160 schizophrenia patients between the ages of 16 and 65 before and after treatment with antipsychotic agents and ECT, and we found that both treatments increased serum BDNF (27). Many studies have examined BDNF levels in schizophrenia and revealed that BDNF influences the therapeutic mechanisms of ECT (28)(29)(30).…”

Section: Thus We Speculated That Abnormal Expression Of Egf May C O mentioning

confidence: 97%

Serum Epidermal Growth Factor is Low in Schizophrenia and Not Affected by Antipsychotics Alone or Combined With Electroconvulsive Therapy

et al. 2020

View full text Add to dashboard Cite

show abstract

Increased serum brain-derived neurotrophic factor levels following electroconvulsive therapy or antipsychotic treatment in patients with schizophrenia

Cited by 38 publications

References 49 publications

Electroconvulsive therapy-induced brain functional connectivity predicts therapeutic efficacy in patients with schizophrenia: a multivariate pattern recognition study

Electroconvulsive therapy-induced brain functional connectivity predicts therapeutic efficacy in patients with schizophrenia: a multivariate pattern recognition study

A Pilot Study on Daily Intensive ECT over 8 Days Improved Positive and Negative Symptoms and General Psychopathology of Patients with Treatment-Resistant Schizophrenia up to 4 Weeks after Treatment

Serum Epidermal Growth Factor is Low in Schizophrenia and Not Affected by Antipsychotics Alone or Combined With Electroconvulsive Therapy

Contact Info

Product

Resources

About